# Weizmann Institute of Science

Source: https://onco.cc/institutions/weizmann/  
OnCo record `weizmann` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Israel's basic research institute, whose HER receptor, p53, single-cell immunology and microbiome discoveries have shaped cancer biology.

## Summary

Founded in 1934 as the Daniel Sieff Institute, the Weizmann Institute of Science created the Moross Integrated Cancer Center in 2016 to link its cancer groups with clinical partners. Yosef Yarden's work on ErbB/HER receptor signalling and antibody combinations, Moshe Oren and Varda Rotter's on p53, Ido Amit's single-cell immunology of tumour myeloid cells, Eran Elinav's microbiome studies and Yardena Samuels's neoantigen discovery in melanoma are widely cited, and Michael Sela's group's early work on combining anti-EGFR antibodies with chemotherapy underpinned patents relevant to cetuximab. The institute's Yeda technology transfer arm has licensed numerous cancer diagnostics and therapeutics, and its scientists collaborate with Sheba, Rambam and international centres.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Weizmann Institute; Moross Integrated Cancer Center
- City: Rehovot, IL
- Type: research-institute
- Website: https://www.weizmann.ac.il

## Sources

- Homepage: https://www.weizmann.ac.il
- Moross Integrated Cancer Center: https://www.weizmann.ac.il/MICC/

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Melanoma](https://onco.cc/cancers/melanoma/)
- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [CRISPR functional genomics](https://onco.cc/technologies/crispr-screens/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Proteomics & phosphoproteomics](https://onco.cc/technologies/proteomics/), [Single-cell & spatial profiling](https://onco.cc/technologies/single-cell-spatial/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [HER2](https://onco.cc/targets/her2/), [TP53](https://onco.cc/targets/tp53/)
- institutions: [Rambam Health Care Campus](https://onco.cc/institutions/rambam/), [Sheba Medical Center](https://onco.cc/institutions/sheba/), [Technion, Israel Institute of Technology](https://onco.cc/institutions/technion/)
- terms: [Neoantigen](https://onco.cc/terms/neoantigen/)
- people: [Alon Chen](https://onco.cc/people/alon-chen/), [Moshe Oren](https://onco.cc/people/moshe-oren/), [Yardena Samuels](https://onco.cc/people/yardena-samuels/), [Yosef Yarden](https://onco.cc/people/yosef-yarden/), [Zelig Eshhar](https://onco.cc/people/zelig-eshhar/)
- key papers: [Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity](https://onco.cc/key-papers/paper-gross-eshhar-chimeric-receptor-pnas-1989/)

---
JSON: https://onco.cc/api/v1/entities/weizmann.json